FOLFiRI Plus Ramucirumab Versus Paclitaxel Plus Ramucirumab for Patients with Advanced or Metastatic Adenocarcinoma of The Stomach or Gastroesophageal Junction As Second-Line Therapy - Interim Safety and Efficacy Results from The Phase II Ramiris Study (AIO-STO-0415) of the German Gastric Group at AIO
Journal title abbreviation:
Oncology Research and Treatment
Year:
2020
Journal volume:
43 Suppl 1
Pages contribution:
58-58
Print-ISSN:
2296-5270
TUM Institution:
III. Medizinische Klinik und Poliklinik (Hämatologie / Onkologie)